title: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
abstract: Mammalian target of rapamycin (mTOR) signaling has been associated with aggressive tumor growth in many cancer models, although its role in urothelial carcinoma (UCC) has not been extensively explored. Expression of phosphorylated mTOR (P-mTOR) and a downstream target, ribosomal S6 protein (P-S6), was identified in 74% (90/121) and 55% (66/121) of muscle-invasive UCCs, respectively. P-mTOR intensity and %positive cells were associated with reduced disease-specific survival (P = 0.04, P = 0.08, respectively). Moreover, P-mTOR intensity corresponded to increased pathological stage (P < 0.01), and mTOR activity was associated with cell migration in vitro. In addition, mTOR inhibition via rapamycin administration reduced cell proliferation in UCC cell lines RT4, T24, J82, and UMUC3 in a dose-dependent manner to 6% of control levels and was significant at 1 nmol/L in J82, T24, and RT4 cells (P < 0.01, P < 0.01, P = 0.03, respectively) and at 10 nmol/L in UMUC3 cells (P = 0.03). Reduced proliferation corresponded with reduced P-S6 levels by Western blot, and effects were ablated by pretreatment of cells with mTOR-specific siRNA. No effects of rapamycin on apoptosis were identified by TUNEL labeling or PARP cleavage. Administration of rapamycin to T24-xenografted mice resulted in a 55% reduction in tumor volume (P = 0.03) and a 40% reduction in proliferation (P < 0.01) compared with vehicle-injected mice. These findings indicate that mTOR pathway activation frequently occurs in UCC and that mTOR inhibition may be a potential means to reduce UCC growth.
authors.affiliation: Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA. hanseld@ccf.org
authors.forename: Donna E
authors.initials: DE
authors.lastname: Hansel
authors.forename: Eric
authors.initials: E
authors.lastname: Platt
authors.forename: Mohammed
authors.initials: M
authors.lastname: Orloff
authors.forename: Jyoti
authors.initials: J
authors.lastname: Harwalker
authors.forename: Swathi
authors.initials: S
authors.lastname: Sethu
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Hicks
authors.forename: Angelo
authors.initials: A
authors.lastname: De Marzo
authors.forename: Roxanne E
authors.initials: RE
authors.lastname: Steinle
authors.forename: Eric D
authors.initials: ED
authors.lastname: Hsi
authors.forename: Dan
authors.initials: D
authors.lastname: Theodorescu
authors.forename: Christina B
authors.initials: CB
authors.lastname: Ching
authors.forename: Charis
authors.initials: C
authors.lastname: Eng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism*; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D020123:Sirolimus / Q000494:pharmacology; D015996:Survival Rate; D058570:TOR Serine-Threonine Kinases; D014183:Transplantation, Heterologous; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000473:pathology
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; C546842:MTOR protein, human; C546843:mTOR protein, mouse; D017346:Protein Serine-Threonine Kinases; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
references.citation: J Biol Chem. 2007 Dec 7;282(49):35803-13
references.pmid: 17928295
references.citation: Cancer Res. 2009 Nov 1;69(21):8256-64
references.pmid: 19843858
references.citation: Br J Cancer. 1999 May;80(5-6):904-8
references.pmid: 10360673
references.citation: Oncogene. 2004 Sep 2;23(40):6788-97
references.pmid: 15273733
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5
references.pmid: 11504907
references.citation: Nat Genet. 1997 May;16(1):64-7
references.pmid: 9140396
references.citation: Urology. 2009 Mar;73(3):665-8; discussion 668-9
references.pmid: 19081609
references.citation: Expert Rev Mol Med. 2008 Feb 04;10:e4
references.pmid: 18241520
references.citation: J Clin Oncol. 1997 Jul;15(7):2564-9
references.pmid: 9215826
references.citation: Oncol Rep. 2006 Jul;16(1):57-63
references.pmid: 16786123
references.citation: J Biol Chem. 2005 Jul 8;280(27):25485-90
references.pmid: 15899889
references.citation: J Pathol. 2001 Jul;194(3):349-57
references.pmid: 11439368
references.citation: Nat Rev Cancer. 2006 Sep;6(9):729-34
references.pmid: 16915295
references.citation: Nat Rev Cancer. 2008 Nov;8(11):851-64
references.pmid: 18846101
references.citation: J Clin Oncol. 2004 Mar 1;22(5):909-18
references.pmid: 14990647
references.citation: J Natl Cancer Inst. 2000 Jun 7;92(11):924-30
references.pmid: 10841828
references.citation: J Biol Chem. 2003 Aug 8;278(32):29655-60
references.pmid: 12777372
references.citation: Hum Mol Genet. 2008 Jul 1;17(13):2006-17
references.pmid: 18397877
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5314-22
references.pmid: 15955899
references.citation: Mol Cancer Ther. 2006 Oct;5(10):2494-502
references.pmid: 17041093
references.citation: Nat Rev Cancer. 2005 Sep;5(9):713-25
references.pmid: 16110317
references.citation: Oncogene. 1997 Jun 26;14(25):3059-66
references.pmid: 9223669
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89
references.pmid: 16467077
references.citation: Mol Carcinog. 2000 Nov;29(3):143-50
references.pmid: 11108659
references.citation: Oncogene. 2004 Jul 29;23(34):5853-7
references.pmid: 15208673
references.citation: Eur J Cancer. 2008 May;44(7):1022-9
references.pmid: 18375114
references.citation: J Cell Biol. 2007 Jul 30;178(3):437-51
references.pmid: 17646396
references.citation: Cancer Cell. 2005 Sep;8(3):179-83
references.pmid: 16169463
references.citation: Mol Cell. 2006 Apr 21;22(2):159-68
references.pmid: 16603397
references.citation: J Urol. 1987 Apr;137(4):663-7
references.pmid: 3560318
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Cancer Res. 2008 Apr 15;68(8):2934-43
references.pmid: 18413763
references.citation: Oncogene. 1993 Apr;8(4):1083-5
references.pmid: 8096074
references.citation: Genes Dev. 2009 Mar 15;23(6):675-80
references.pmid: 19261747
references.citation: Urology. 2007 Jan;69(1 Suppl):62-79
references.pmid: 17280909
references.citation: J Cell Physiol. 2000 Mar;182(3):311-22
references.pmid: 10653597
references.citation: Expert Rev Anticancer Ther. 2008 Feb;8(2):283-92
references.pmid: 18279068